1,7-二氮杂环十二烷 | 294-76-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1,7-二氮杂环十二烷
• 英文名称: 1,7-diazacyclododecane
• CAS: 294-76-8
• 化学式: C₁₀H₂₂N₂
• mdl: MFCD20547669
• 分子量: 170.298
• InChiKey: MQPSNACUPPXMSB-UHFFFAOYSA-N

物化性质

• 沸点：
  263.5±8.0 °C(Predicted)
• 密度：
  0.830±0.06 g/cm3(Predicted)
• 熔点：
  14 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,2-[氧基双(2,1-亚乙基氧基亚甲基)]双环氧乙烷 、 1,7-二氮杂环十二烷 以 四氢呋喃 、 乙醇 为溶剂， 反应 10.0h， 以22%的产率得到3,13-dihydroxy-5,8,11-trioxa-1,15-diazabicyclo<13.5.5>pentacosane
  参考文献：
  名称：

  Luk'yanenko, N. G.; Reder, A. S., Journal of Organic Chemistry USSR (English Translation), 1989, vol. 25, # 2.2, p. 343 - 352

  摘要：

  DOI：
• 作为产物：
  描述：

  5-hydroxypentyl p-toluenesulfonate 在 4-二甲氨基吡啶 、 氢溴酸 、 sodium hydride 、 三乙胺 、 苯酚 作用下， 以 二氯甲烷 为溶剂， 反应 88.5h， 生成 1,7-二氮杂环十二烷
  参考文献：
  名称：

  Boerjesson, L.; Welch, C. J., Acta Chemica Scandinavica, 1991, vol. 45, # 6, p. 621 - 626

  摘要：

  DOI：

文献信息

• FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
  申请人：Abbisko Therapeutics Co., Ltd.

  公开号：US20190270742A1

  公开（公告）日：2019-09-05

  Provided are an FGFR4 inhibitor having the structure of formula (I), and a preparation method therefor and the use thereof. The compound has a very strong inhibitory effect on FGFR4 kinase activity and has a very high selectivity, and can be widely used in the preparation of a drug for treating cancers, especially prostate cancer, liver cancer, pancreatic cancer, esophageal carcinomas, gastric cancer, lung cancer, breast cancer, ovarian carcinomas, colon cancer, skin cancer, glioblastomas or rhabdomyosarcomas, and is expected to be developed into a new generation of FGFR4 inhibitor drugs.

  提供一种具有结构式（I）的FGFR4抑制剂，以及其制备方法和用途。该化合物对FGFR4激酶活性具有非常强的抑制作用，并具有非常高的选择性，可以广泛用于制备用于治疗癌症的药物，特别是前列腺癌、肝癌、胰腺癌、食管癌、胃癌、肺癌、乳腺癌、卵巢癌、结肠癌、皮肤癌、胶质母细胞瘤或横纹肌肉瘤，并有望被开发成新一代的FGFR4抑制剂药物。
• DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE
  申请人：Celtaxsys, Inc.

  公开号：US20160272649A1

  公开（公告）日：2016-09-22

  This invention is directed to compounds of formula (I): where r, q, R, R 2 , R 3 , R 4 , R 5a , R 5b , R 5c , R 6a , R 6b , R 6c , R 7 , R 8 , and R 9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A 4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.

  本发明涉及化合物的公式（I）： 其中r，q，R，R2，R3，R4，R5a，R5b，R5c，R6a，R6b，R6c，R7，R8和R9如本文所述，可以作为单一立体异构体或立体异构体混合物，或其药学上可接受的盐，溶剂合物，笼合物，多晶形式，铵离子，N-氧化物或其前药; 这些化合物是白三烯A4水解酶抑制剂，因此在治疗炎症性疾病方面有用。本发明还揭示了包含该化合物的制药组合物以及制备该化合物的方法。
• FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof
  申请人：Abbisko Therapeutics Co., Ltd.

  公开号：US10968220B2

  公开（公告）日：2021-04-06

  Provided are an FGFR4 inhibitor having the structure of formula (I), and a preparation method therefor and the use thereof. The compound has a very strong inhibitory effect on FGFR4 kinase activity and has a very high selectivity, and can be widely used in the preparation of a drug for treating cancers, especially prostate cancer, liver cancer, pancreatic cancer, esophageal carcinomas, gastric cancer, lung cancer, breast cancer, ovarian carcinomas, colon cancer, skin cancer, glioblastomas or rhabdomyosarcomas, and is expected to be developed into a new generation of FGFR4 inhibitor drugs.

  本发明提供了一种具有式(I)结构的FGFR4抑制剂及其制备方法和用途。该化合物对 FGFR4 激酶活性有很强的抑制作用，并具有很高的选择性，可广泛用于制备治疗癌症的药物，特别是前列腺癌、肝癌、胰腺癌、食管癌、胃癌、肺癌、乳腺癌、卵巢癌、结肠癌、皮肤癌、胶质母细胞瘤或横纹肌肉瘤，有望开发成新一代 FGFR4 抑制剂药物。
• Enhanced Product Selectivity in Continuous N-Methylation of Amino Alcohols over Solid Acid–Base Catalysts with Supercritical Methanol
  作者：Tomoharu Oku、Takao Ikariya

  DOI：10.1002/1521-3773(20020916)41:18<3476::aid-anie3476>3.0.co;2-5

  日期：2002.9.16
• Palladium-catalyzed ring-opening reactions of 1-acetyl-4-vinyl-2-azetidinones and 1-sulfonyl-2-vinylazetidines. Role of intramolecular participation of amide anion
  作者：Akiharu Satake、Hideo Ishii、Isao Shimizu、Yoichi Inoue、Hajime Hasegawa、Akio Yamamoto

  DOI：10.1016/0040-4020(95)00217-v

  日期：1995.5

  Ring opening reactions of 1-acetyl-4-vinyl-2-azetidinones in the presence of palladium(0)-n-Bu(3)P catalyst gave 2,4-pentadienamides in good yields, whereas 2-substituted-1,3-dienes were produced by the reaction of 1-sulfonyl-2-vinyl-2-methylazetidines. Ring opening dimerization took place to give 1,7-ditrifluoromethanesulfonyl-1,7-diazacyclododecane in the reaction of 1-trifluoromethanesulfonyl-2-vinylazetidine.